DDB1
ENSG00000167986
Target class
Unclassified protein
Chromosome
11
Approved drugs
4
Clinical candidates (approved and in development)
5
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 5
- Chemical probe available
- No
- Target name
- DDB1
- Gene name
- Damage specific DNA binding protein 1
- Gene symbol
- DDB1
- Protein name
- DNA damage-binding protein 1 (DDB p127 subunit) (DNA damage-binding protein a) (DDBa) (Damage-specific DNA-binding protein 1) (HBV X-associated protein 1) (XAP-1) (UV-damaged DNA-binding factor) (UV-damaged DNA-binding protein 1) (UV-DDB 1) (XPE-binding factor) (XPE-BF) (Xeroderma pigmentosum group E-complementing protein) (XPCe)
- Gene biotype
- Protein coding
- Gene family
- Nucleotide excision repair
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 234.56
- Tissue specificity (Gini)
- 0.252
- Tissue specificity (tau)
- 0.699
- KEGG gene identifiers
- hsa:1642
- Protein interaction confidence
- 0.866872
- Protein interaction partners
- 180
- R-HSA-110314
- R-HSA-5696394
- R-HSA-5696395
- R-HSA-5696400
- R-HSA-6781823
- R-HSA-6781827
- R-HSA-6782135
- R-HSA-6782210
- R-HSA-8951664
- End position
- 61342596
- Start position
- 61299447
- Chromosome
- 11
- Strand
- Reverse
- Cytoplasm . Nucleus . Note=Primarily cytoplasmic (PubMed:10777491, PubMed:11673459). Translocates to the nucleus following UV irradiation and subsequently accumulates at sites of DNA damage (PubMed:10777491, PubMed:11673459). More concentrated in nuclei than in cytoplasm in germinal vesicle (GV) stage oocytes, zygotes and the 2-cell stage, but distributed in the cytoplasm at the MII-stage oocytes (By similarity). .
- End piece
- Mid piece
- Nucleoplasm
- Principal piece
- PubMed 10777491
- PubMed 11673459
- PubMed 18593899
- Tissue specificity (tau)
- 0.698916
- Expression inequality (Gini)
- 0.251718
Expression in transcripts per million
- Adrenal Gland
- 234.56
- Cells - Cultured fibroblasts
- 165.1
- Testis
- 131.43
- Ovary
- 126.56
- Cells - EBV-transformed lymphocytes
- 122.7
Expression in transcripts per million
- Adrenal Gland234.56
- Cells - Cultured fibroblasts165.1
- Testis131.43
- Ovary126.56
- Cells - EBV-transformed lymphocytes122.7
- Nerve - Tibial100.42
- Uterus100.11
- Skin - Sun Exposed (Lower leg)97.15
- Fallopian Tube95.76
- Pituitary95.16
- Cervix - Endocervix93.37
- Bladder92.55
- Skin - Not Sun Exposed (Suprapubic)90.84
- Thyroid90.03
- Artery - Tibial89.65
- Muscle - Skeletal87.74
- Brain - Cerebellar Hemisphere85.3
- Cervix - Ectocervix83.8
- Artery - Aorta83.29
- Brain - Cerebellum81.94
- Vagina80.06
- Esophagus - Gastroesophageal Junction77.75
- Adipose - Subcutaneous76.39
- Breast - Mammary Tissue75.73
- Esophagus - Muscularis74.72
And 29 more, listed on the interactive page.
- GO:0006281
- GO:0006289
- GO:0006511
- GO:0006974
- GO:0007056
- GO:0010498
- GO:0016567
- GO:0019076
- GO:0034644
- GO:0043161
- GO:0044725
- GO:0045070
- GO:0045732
- GO:0046726
- GO:0051702
- GO:0070914
- GO:1901990
- GO:0000781
- GO:0005576
- GO:0005634
- GO:0005654
- GO:0005730
- GO:0005737
- GO:0031464
- GO:0031465
- GO:0032991
- GO:0070062
- GO:0080008
- GO:0003677
- GO:0003684
- GO:0005515
- GO:0030674
- GO:0044877
- GO:0071987
- GO:0097602
- GO:0160072
Related records
Trials (1,854)
- "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "
- [Effects of Selected Statins on Cardiovascular Parameters in Healthy Volunteers]
- 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
- 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting
- 5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting
- 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
- A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
- A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults
- A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
- A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia
- A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma
Drugs (5)
- Iberdomide CRL4(CRBN) E3 ubiquitin ligase modulator
- Lenalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator
- Lenalidomide hydrochloride monohydrate CRL4(CRBN) E3 ubiquitin ligase modulator
- Pomalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor
- Thalidomide CRL4(CRBN) E3 ubiquitin ligase inhibitor